Smartest Doc
Roche on track for full-year targets - good sales growth in first quarter Full Text
Roche, 04/13/2012
Roche CEO Severin Schwan commenting on the Group's first quarter 2012 performance: With sales advancing 2% in the first three months, we remain on track to achieve our targets for the full–year. After the rapid approvals of Zelboraf and Erivedge we can now make these innovative medicines available to patients suffering from severe forms of skin cancer. The ongoing positive newsflow on our product pipeline underscores our growth prospects for the coming years: since the beginning of the year we have announced positive results from five out of five key late–stage clinical trials.